Cahaba Wealth Management Inc. Sells 140 Shares of Zoetis Inc. (NYSE:ZTS)

Cahaba Wealth Management Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 10.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,228 shares of the company’s stock after selling 140 shares during the period. Cahaba Wealth Management Inc.’s holdings in Zoetis were worth $242,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Evermay Wealth Management LLC lifted its holdings in Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the period. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $26,000. VisionPoint Advisory Group LLC bought a new stake in shares of Zoetis during the 2nd quarter worth about $29,000. Finally, Moisand Fitzgerald Tamayo LLC grew its stake in Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after buying an additional 96 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the completion of the transaction, the executive vice president now owns 17,569 shares of the company’s stock, valued at approximately $3,363,233.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have sold 2,209 shares of company stock valued at $408,453. 0.15% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Shares of NYSE ZTS traded down $2.01 during mid-day trading on Tuesday, reaching $165.01. The company had a trading volume of 2,376,954 shares, compared to its average volume of 2,720,826. Zoetis Inc. has a one year low of $151.03 and a one year high of $201.92. The business’s 50-day simple moving average is $184.62 and its 200 day simple moving average is $181.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The firm has a market cap of $75.47 billion, a price-to-earnings ratio of 32.55, a PEG ratio of 2.58 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the prior year, the business earned $1.15 earnings per share. Zoetis’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, research analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.05%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is presently 34.12%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZTS. BNP Paribas began coverage on shares of Zoetis in a research report on Thursday, December 7th. They set an “outperform” rating and a $237.00 price objective for the company. Piper Sandler lifted their price target on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Barclays upped their price objective on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, February 14th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, The Goldman Sachs Group upped their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $222.11.

Get Our Latest Stock Analysis on ZTS

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.